表皮生长因子受体（EGFR）家族是一类跨膜蛋白，因其在多种恶性肿瘤中的关键作用而被高度视为抗癌靶点。针对 ErbB 受体的标准癌症治疗包括酪氨酸激酶抑制剂 (TKI) 和单克隆抗体 (mAb)。尽管它们具有显着的生存益处，但获得性耐药性阻碍了治疗结果的实现。抗 ErbB 方法的最新进展，例如抑制肽、纳米抗体、靶向蛋白降解策略和双特异性抗体 (BsAb)，旨在克服这种耐药性。最近，对 ErbB 家族细胞表面相互作用组的新见解为通过靶向 ErbB 伙伴的特定域来调节 ErbB 信号通路开辟了新途径。在这里，我们回顾了 ErbB 靶向的最新进展，并阐明了新兴范例，这些范例强调了含有 EGF 结构域的蛋白质 (EDCP) 作为新的 ErbB 靶向途径的重要性。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

The epidermal growth factor receptor (EGFR) family is a class of transmembrane proteins, highly regarded as anticancer targets due to their pivotal role in various malignancies. Standard cancer treatments targeting the ErbB receptors include tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). Despite their substantial survival benefits, the achievement of curative outcomes is hindered by acquired resistance. Recent advancements in anti-ErbB approaches, such as inhibitory peptides, nanobodies, targeted-protein degradation strategies, and bispecific antibodies (BsAbs), aim to overcome such resistance. More recently, emerging insights into the cell surface interactome of the ErbB family open new avenues for modulating ErbB signaling by targeting specific domains of ErbB partners. Here, we review recent progress in ErbB targeting and elucidate emerging paradigms that underscore the significance of EGF domain-containing proteins (EDCPs) as new ErbB-targeting pathways.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.